Curated news and analysis on clinical trials, drug approvals, and medical research.
Recent advances in chimeric antigen receptor cell therapies highlight improved designs for CAR-T and CAR-NK treatments, with new strategies addressing efficacy and safety challenges in both hematologic and solid tumors.
Novo Nordisk announced it will reduce list prices of Wegovy, Ozempic, and Rybelsus by 35% to 50% to $675 monthly starting in 2027, aiming to regain market share from rival Eli Lilly and improve access for high-deductible patients.
New target trial emulation study finds GLP-1 receptor agonists associated with lower heart failure hospitalization risk versus DPP-4 inhibitors and similar risk to SGLT-2 inhibitors in type 2 diabetes patients.
Novartis announced positive Phase III ALIGN results for Vanrafia in IgA nephropathy and plans to build a new radioligand therapy manufacturing site in Denton, Texas, operational by 2028.
The iShares Biotechnology ETF (IBB) has gained 27.39% over the past year as of February 25, 2026, with over $8.64 billion in assets under management and a 0.44% expense ratio.
The FDA accepted Viatris' application for phentolamine ophthalmic solution 0.75% to treat presbyopia, with a decision expected October 2026. Separately, the agency approved Yuvezzi, a once-daily combination eye drop for age-related near vision loss.
Industry leaders highlight advances in AI-enabled trial monitoring, real-world data interoperability, and protocol-driven eSource systems, while emphasizing the need for community engagement in diversity efforts and addressing operational risks in rare disease trials.
The FDA has announced a major policy shift ending the "two-trial dogma," allowing drug approvals based on one adequate and well-controlled study plus confirmatory evidence, with heightened focus on study design quality.
The FDA approved BYSANTI (milsaperidone) for bipolar I disorder and schizophrenia in adults, and accepted Vanda's BLA filing for imsidolimab to treat Generalized Pustular Psoriasis with a target action date of December 12, 2026.
Protein biomarkers and self-sampling methods are transforming drug development and occupational health surveillance, enabling more efficient clinical trials, improved target selection, and minimally invasive continuous monitoring.
Recent studies examine how doomscrolling disrupts sleep, indoor air quality affects asthma, pet ownership impacts older adults, and bedroom temperature influences rest quality in seniors.
The global precision medicine market reached $98.87 billion in 2024 and is projected to grow at 14.8% CAGR through 2033, driven by genomic sequencing advances, chronic disease prevalence, and AI-driven diagnostics adoption.
Indian drugmaker Dr Reddy's Laboratories is preparing to launch its generic semaglutide injection under the brand name Obeda in March 2026, as patent protection expires in India. The company plans to price it up to 60% below branded products.
The global pharmaceutical market reached nearly $1.7 trillion in value, with Johnson & Johnson leading prescription sales at approximately $55.8 billion while Merck & Co. topped research and development investment at $17.8 billion.
Health Canada released proposed Clinical Trials Regulations in December 2025 that would establish a new regulatory framework for drug trials, replacing existing rules with a streamlined, risk-based approach aimed at improving access to innovative therapies.
Ultrasensitive testing of tumor DNA in blood and urine may identify muscle-invasive bladder cancer patients who can safely forgo radical cystectomy, with 69% achieving 3-year bladder-intact survival after systemic therapy.
The FDA approved acalabrutinib combined with venetoclax for chronic lymphocytic leukemia and small lymphocytic leukemia based on phase III trial results. Separately, Yale researchers identified CD25 protein complex as a new drug target for aggressive leukemias.
Axogen reported Q4 2025 revenue of $59.9 million, up 21.3% year-over-year, but swung to a net loss due to FDA BLA approval costs. The company secured 12 years of market exclusivity for Avance Nerve Graft and guided 2026 revenue growth of at least 18%.
Palvella Therapeutics announced positive topline results from its Phase 3 SELVA study of QTORIN 3.9% rapamycin for microcystic lymphatic malformations, meeting all primary and secondary endpoints with strong tolerability. The company plans an NDA submission in H2 2026.
Phase III FENtrepid trial results show investigational BTK inhibitor fenebrutinib met its primary endpoint of non-inferiority to ocrelizumab in primary progressive MS, with a 12% reduction in disability progression risk and strongest effect on upper limb function.
